Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.

  title={Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.},
  author={X. Liu and N. Shin and H. Koblish and Gengjie Yang and Q. Wang and K. Wang and L. Leffet and M. Hansbury and Beth E. Thomas and Mark J Rupar and P. Waeltz and K. Bowman and Padmaja Polam and R. Sparks and E. Yue and Y. Li and R. Wynn and J. Fridman and T. Burn and A. Combs and R. Newton and P. Scherle},
  volume={115 17},
  • X. Liu, N. Shin, +19 authors P. Scherle
  • Published 2010
  • Biology, Medicine
  • Blood
  • Indoleamine 2,3-dioxygenase-1 (IDO1; IDO) mediates oxidative cleavage of tryptophan, an amino acid essential for cell proliferation and survival. IDO1 inhibition is proposed to have therapeutic potential in immunodeficiency-associated abnormalities, including cancer. Here, we describe INCB024360, a novel IDO1 inhibitor, and investigate its roles in regulating various immune cells and therapeutic potential as an anticancer agent. In cellular assays, INCB024360 selectively inhibits human IDO1… CONTINUE READING
    356 Citations
    Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
    • 68
    Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies
    • 8
    • PDF
    Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
    • 279
    IDO1 in cancer: a Gemini of immune checkpoints
    • 70
    • PDF


    A Novel Cancer Therapy by Skin Delivery of Indoleamine 2,3-Dioxygenase siRNA
    • 67
    • PDF
    Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection
    • 337
    Inhibition of  T Cell Proliferation by Macrophage Tryptophan Catabolism
    • 1,386
    • PDF